Profil
Jan Honoré is currently the Head at PM Equity Partner SARL since 2014.
Prior to this, he held positions as Chairman at Zymenex A and Zealand Pharma A, Director at Biovotion AG, and Partner at BI Technology A from 2003 to 2006.
Mr. Honoré has an undergraduate and graduate degree from the University of Aarhus.
Aktive Positionen von Jan Honoré
| Unternehmen | Position | Beginn |
|---|---|---|
PM Equity Partner SARL
PM Equity Partner SARL Investment ManagersFinance PMEP invests in technology companies located in Europe and North America. It focuses on environmental health, agriculture, human health and lifestyle. | Private Equity Investor | 01.10.2014 |
Ehemalige bekannte Positionen von Jan Honoré
| Unternehmen | Position | Ende |
|---|---|---|
BI Technology A/S
BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Private Equity Investor | 26.12.2006 |
Biovotion AG
Biovotion AG Packaged SoftwareTechnology Services Develops wearable sensing software for health monitoring solutions | Direktor/Vorstandsmitglied | - |
Zymenex A/S
Zymenex A/S BiotechnologyHealth Technology Engages in the research and development of therapeutics for life threatening diseases | Vorsitzender | - |
| ZEALAND PHARMA A/S | Vorsitzender | - |
Ausbildung von Jan Honoré
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
University of Aarhus
University of Aarhus Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
BI Technology A/S
BI Technology A/S Investment ManagersFinance BI-T is an active venture capital investment manager following a hands-on approach and investing primarily in high-growth life science technology companies with global expansion potential. Investment criteria include an experienced management team, an innovative business concept with a competitive edge based on proven distinctive technology, a clearly defined medical need and patient population, and adequate IP protection by a strong patent portfolio. The firm focuses on unlisted, research-based biotechnology companies dedicated to developing profitable pharmaceuticals for the treatment of human diseases. They pay attention to unmet medical needs, potential medical improvements and major markets. They favor companies with advanced R&D supporting a market launch in the foreseeable future. They invest primarily in Europe, particularly in Denmark and the Nordic countries, and occasionally in the US where they co-invest with third parties. BI-T also invests in the energy technology field, focusing on renewable energy, energy storage, conversion and distribution as well as on improvements to the traditional energy sector. They aim to support the profitable development of sustainable and environmentally-clean alternative energies such as wind, water and solar power as well as clean fuels such as natural gas, hydrogen and biofuels. They invest in Denmark and Europe through direct equity participations in share increases, and target companies with attractive exit potential. They favor startups and early-expansion-stage companies with a credible business model based on proprietary products or services. BI-T provides intensive advisory and consultancy services to their portfolio companies. They follow up their initial investment with additional capital. The firm exits their investments through IPOs and trade sales, and their targeted exit horizon is three to ten years. Finally, the firm is involved in private equity investing in emerging markets in Africa and Asia, particularly in Vietnam, South Africa, East Africa and Egypt. Their investments are often supported by DANIDA-Danish International Development Assistance grants. Investments in Southeast Asia are managed out of a representative office in Ho Chi Minh City, Vietnam. | Finance |
Zymenex A/S
Zymenex A/S BiotechnologyHealth Technology Engages in the research and development of therapeutics for life threatening diseases | Health Technology |
Zealand Pharma A/S
Zealand Pharma A/S BiotechnologyHealth Technology Operates as a biotechnology company that discovers and develops peptide based medicines | Health Technology |
Biovotion AG
Biovotion AG Packaged SoftwareTechnology Services Develops wearable sensing software for health monitoring solutions | Technology Services |
PM Equity Partner SARL
PM Equity Partner SARL Investment ManagersFinance PMEP invests in technology companies located in Europe and North America. It focuses on environmental health, agriculture, human health and lifestyle. | Finance |
















